Influence of medical intervention on sympathetic activity in heart failure

dele Milliano, P.A.R.

Citation for published version (APA):
Contents

I. Introduction

II. Heart failure, pathophysiology and compensatory mechanisms.

III. Sympathetic activation in heart failure.

IV. Beta-blockers in heart failure: hemodynamics, clinical effects and modes of action.

V. Increased myocardial ^125I-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure.
Heart 1996; 76:218-222

VI. Beneficial effects of metoprolol on myocardial sympathetic function.
Evidence from a randomized, placebo controlled study in patients with congestive heart failure.
Paul A.R. de Milliano, MD, Andre C. de Groot, MD, Jan G.P. Tijssen, MD, PhD, Berthe L.F. van Eck-Smit, MD, PhD, Pieter A. van Zwieten, MD, PhD, and Kong I. Lie, MD, PhD.
American Heart Journal: in press.

VII. Relationship between cardiac MIBG uptake and hemodynamic, functional and neurohormonal parameters in patients with heart failure.
Paul A.R. de Milliano, MD; Berthe L.F. van Eck-Smit, MD, PhD; Pieter A. van Zwieten, MD, PhD; Andre C. de Groot, MD; Jan G.P. Tijssen, MD, PhD; Kong I. Lie, MD, PhD.
European Journal of Heart Failure 2001; 3:693-697

VIII. Cardiac 123I-MIBG imaging and clinical variables in risk stratification in patients with heart failure treated with β-blockers.
Nuclear Medicine Communications: in press.
IX. Metoprolol-induced changes in myocardial $^{123}$I-Metaiodobenzylguanidine uptake in Parkinson’s disease.
Paul A.R. de Milliano, MD; Berthe L.F. van Eck-Smit, MD; Andre C. de Groot, MD; Kong I. Lie, MD, PhD.

X. General discussion and clinical implications.

XI. Summary
Samenvatting

Dankwoord

Curriculum Vitae